เอกสารอ้างอิง
[1]. McVary KT. Clinical manifestations and diagnosis evaluation of benign prostatic hyperplasia. [Internet]. Hudson, Ohio: Hudson, Ohio: Wolters Kluwer UpToDate, Inc.; 2022 [cited 25 Jul 2022].
[2]. Lerner LB, McVary, KT, Barry MJ et al: Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline part I, initial work-up and medical management. Journal of Urology. 2021; 206: 806.
[3]. Nickel JC, Aaron L, Barkin J, Elterman D, Nachabé M, Zorn KC. Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. Canadian Urological Association Journal. 2018 Oct;12(10):303-312.
[4]. Alfuzosin. In: Specific Lexicomp Online Database [database on the internet]. Hudson (OH): Lexicomp Inc.: 2022 [updated 2022 Jul 9; cited 2022 Jul 10]. Available from: https://online.lexi.com. Subscription required to view.
[5]. Doxazosin. In: Specific Lexicomp Online Database [database on the internet]. Hudson (OH): Lexicomp Inc.: 2022 [updated 2022 Jul 7; cited 2022 Jul 10]. Available from: https://online.lexi.com. Subscription required to view.
[6]. Kara O, Yazici M. Is the double dose alpha-blocker treatment superior than the single dose in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia? Urology Journal. 2014 Jul 8;11(3):1673-7.
[7]. Lee KC, Kim JG, Cho SY, Jeon JS, Cho IR. Comparison of different alpha-blocker combinations in male hypertensives with refractory lower urinary tract symptoms. Korean Journal of Andrology. 2011 Dec 1;29(3):242-50.